V.A. Miller

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

Francis M. Sirotnak, Maureen F. Zakowski, V.A. Miller et al. · PubMed · 2000 · 761 citations

Immunology, Pharmacotherapy, Human Tumor Xenografts +17

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer

Alexa B. Schrock, Ching Ouyang, Jaideep Sandhu et al. · Annals of Oncology · 2019 · 616 citations

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer

Aria Vaishnavi, Marzia Capelletti, Anh T. Le et al. · Nature Medicine · 2013 · 582 citations · Full text

Oncogenic Agent, Pathology, Cancer Genetics +3

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer

Christian Grommes, Geoffrey R. Oxnard, Mark G. Kris et al. · Neuro-Oncology · 2011 · 341 citations · Full text

Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing

Christine H. Chung, Violeta Beleva Guthrie, David L. Masica et al. · Annals of Oncology · 2015 · 202 citations · Full text